MPN blast phase: clinical challenge and assessing response

Leuk Res. 2012 Dec;36(12):1496-7. doi: 10.1016/j.leukres.2012.08.026. Epub 2012 Sep 19.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Blast Crisis* / pathology
  • Blast Crisis* / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Janus Kinase 2 / genetics
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / pathology
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / therapy
  • Mutation
  • Myeloablative Agonists / therapeutic use
  • Myeloproliferative Disorders* / pathology
  • Myeloproliferative Disorders* / therapy
  • Polycythemia Vera / pathology
  • Polycythemia Vera / therapy
  • Primary Myelofibrosis / pathology
  • Primary Myelofibrosis / therapy
  • Protein Kinase Inhibitors / therapeutic use
  • Thrombocythemia, Essential / pathology
  • Thrombocythemia, Essential / therapy
  • Transplantation Conditioning / methods

Substances

  • Histone Deacetylase Inhibitors
  • Myeloablative Agonists
  • Protein Kinase Inhibitors
  • JAK2 protein, human
  • Janus Kinase 2